As of 2026-10-06, the Intrinsic Value of Viking Therapeutics Inc (VKTX) is -22.92 USD. This VKTX valuation is based on the model Peter Lynch Fair Value. With the current market price of 29.28 USD, the upside of Viking Therapeutics Inc is -178.29%.
Based on its market price of 29.28 USD and our intrinsic valuation, Viking Therapeutics Inc (VKTX) is overvalued by 178.29%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -22.92 - -22.92 | -22.92 | -178.29% |
| P/E | (136.71) - (165.08) | (155.19) | -630.0% |
| DDM - Stable | (35.79) - (118.35) | (77.07) | -363.2% |
| DDM - Multi | (0.38) - (0.95) | (0.54) | -101.8% |
| Market Cap (mil) | 2,517.53 |
| Beta | 0.89 |
| Outstanding shares (mil) | 85.98 |
| Enterprise Value (mil) | 2,391.78 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.45% |
| Cost of Debt | 5.00% |
| WACC | 8.06% |